ATXI
NASDAQAvenue Therapeutics Inc.
Price$0.42+0.00 (+0.00%)
2025-12-102026-03-17
News · 26 weeks10-100%
2025-12-142026-06-07
Mix290d
- SEC Filings2(100%)
Latest news
25 items- SECSEC Form 10-Q filed by Avenue Therapeutics Inc.10-Q - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
- SECSEC Form 10-K filed by Avenue Therapeutics Inc.10-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
- SECAvenue Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
- PRAvenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe DiseaseATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for rare and neurologic diseases, today announced that it has entered into an exclusive worldwide license agreement with Duke University for patents and know-how pertaining to ATX-04 (clenbuterol), a well-characterized small-molecule β2-adrenergic agonist, in clinical development for the treatment of Pompe disease. Pompe d
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Avenue Therapeutics Inc.SCHEDULE 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)
- INSIDERLarge owner Fortress Biotech, Inc. was granted 111,209 shares, increasing direct ownership by 34% to 439,733 units (SEC Form 4)4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
- SECAvenue Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
- SECSEC Form EFFECT filed by Avenue Therapeutics Inc.EFFECT - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
- SECSEC Form POS AM filed by Avenue Therapeutics Inc.POS AM - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
- SECSEC Form RW filed by Avenue Therapeutics Inc.RW - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
- SECSEC Form DEF 14A filed by Avenue Therapeutics Inc.DEF 14A - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
- SECAvenue Therapeutics Inc. filed SEC Form 8-K: Shareholder Director Nominations, Other Events8-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
- SECSEC Form 10-Q filed by Avenue Therapeutics Inc.10-Q - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
- SECAvenue Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Other Events, Financial Statements and Exhibits8-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
- SECSEC Form 10-Q filed by Avenue Therapeutics Inc.10-Q - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
- SECSEC Form 25-NSE filed by Avenue Therapeutics Inc.25-NSE - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)
- SECSEC Form 10-Q filed by Avenue Therapeutics Inc.10-Q - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
- SECAvenue Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits8-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Avenue Therapeutics Inc.SCHEDULE 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)
- INSIDERLarge owner Fortress Biotech, Inc. was granted 33,724 shares, increasing direct ownership by 11% to 328,524 units (SEC Form 4)4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
- SECSEC Form 10-K filed by Avenue Therapeutics Inc.10-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
- SECAvenue Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
- SECAvenue Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Avenue Therapeutics Inc.SCHEDULE 13G/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Avenue Therapeutics Inc.SCHEDULE 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)
ATXI FAQ
6 questionsWhat does Avenue Therapeutics Inc. do?
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was incorporated in 2015 and is based in New York, New York.Where does ATXI stock trade?
Avenue Therapeutics Inc. (ATXI) is listed on NASDAQ.What sector and industry is ATXI in?
Avenue Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Avenue Therapeutics Inc. go public?
Avenue Therapeutics Inc. (ATXI) completed its IPO in 2017.What companies are similar to ATXI?
Notable peers in the same industry include KDNY (Chinook Therapeutics Inc.), RLMD (Relmada Therapeutics Inc.), CKPT (Checkpoint Therapeutics Inc.), FBIO (Fortress Biotech Inc.), MBIO (Mustang Bio Inc.). Compare ATXI side-by-side with any of them on Quantisnow.How can I track ATXI on Quantisnow?
Quantisnow aggregates Avenue Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ATXI to receive live email and push alerts on every new disclosure.